Monthly research recap
Psilocybin research: July 2026
What July 2026's 25 new studies found, synthesized from the papers below. All Psilocybin research →
The synthesis
Synthesized from 25 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Psilocybin, magic mushrooms, psilocin, psychedelic mushrooms, then ranked by relevance.
Research published in July 2026 indicates that psilocybin shows promise for treating conditions such as treatment-resistant depression, demoralization in cancer, and anorexia nervosa, with effects ranging from moderate to large, though many studies are small, open-label, or pilot in nature. Mechanistic studies in mice reveal that psilocybin's effects depend on brain state, 5-HT2A receptors, and specific neural circuits, and that its neuroplastic effects are modulated by environmental context. However, the evidence is limited by small sample sizes, lack of long-term follow-up, and inconsistent reporting practices across trials, so conclusions about durability and generalizability remain tentative.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Psychedelic drug action at dendrites is gated by behavioral state and serotonin receptors 2026 | experimental study | Supports | Psilocybin transiently increases dendritic calcium event rates in apical tufts in a brain state- and 5-HT2A receptor-dependent manner, and alters the predictive relationship between acute dendritic calcium signaling and subsequent spine formation. | |
| Learnings from a hybrid communities of practice group therapy model to support psilocybin-assisted therapy for patients with a terminal diagnosis 2026 | qualitative study | 25 | Supports | Group-administered psilocybin-assisted therapy supported by virtual communities of practice is feasible, safe, and provides psychosocial benefits for palliative cancer patients. |
| A randomized, double-blind, placebo-controlled single-ascending-dose study to identify a non-hallucinogenic dose of psilocybin in healthy adults. 2026 | Phase 1, randomized, double-blind, placebo-controlled, single ascending dose study | 56 | Supports | Low doses of psilocybin produce perceptible pharmacological effects without significant perceptual alterations, cognitive impairment, or increased anxiety. |
| Psilocybin produces amplified acute responses and sex-specific long-term increases in sensorimotor gating in the mGlu5 knockout mouse model of schizophrenia 2026 | experimental study using knockout mouse model | Mixed | Disrupted mGlu5 signaling amplifies acute responses to psilocybin and reveals a sex-dependent long-term effect on sensorimotor gating. | |
| Quantifying psilocybin exposure in a natural product–based retreat setting: An observational field method for dose measurement 2026 | observational field evaluation | 11 | Unclear | Psilocybin concentration varied 2.6-fold between batches, making gram-based dosing inadequate for estimating psychoactive substance exposure. |
| Silence is golden: Documenting the speech production of participants and support providers in psilocybin administration sessions for the treatment of post-traumatic stress disorder 2026 | randomized controlled trial | 22 | Supports | During psilocybin administration sessions, 78% of time was filled with silence, and support was minimally enacted but experientially salient. |
| Psychedelic Therapies in the Management of Post-Traumatic Stress Disorder 2026 | review | Supports | Psychedelic therapies, particularly MDMA-assisted therapy, represent a potential breakthrough by targeting the underlying causes of PTSD rather than merely suppressing symptoms. | |
| The ANCHOR Framework for Psychedelic Accompaniment 2026 | theoretical or philosophical paper | Unclear | Argues that psychedelic-assisted interventions are complex and context-sensitive, and proposes the ANCHOR framework for psychedelic preparation, support, and integration. | |
| From trial to clinic: psilocybin’s efficacy in routine treatment-resistant depression 2026 | observational cohort | 19 | Supports | Among 19 adults with treatment-resistant depression treated with psilocybin in routine clinical practice, clinician-rated depressive symptoms decreased substantially, with a Montgomery–Åsberg reduction of approximately 11 points and Hedges' g ≈ 1.4. |
| Psilocybin's effect on human brain synaptic plasticity. 2026 | observational cohort | 15 | Mixed | Psilocybin's effect on synaptic density is modulated by environmental context, with a therapeutic-like setting associated with greater increases in synaptic density and more intense mystical-type experiences than an MRI scanner setting. |
| Shurooms: The First Ethnomycological Study from Within the African Initiatory Tradition — Ewe, Soma, and the Ceremonial Architecture of Psilocybin Healing (N = 300+) 2026 | ethnographic study with participant-observation | 300 | Supports | A four-part typology of healing and a Three-Pillar theoretical framework emerge from participant-observation across more than 300 psilocybin ceremonies conducted within the African initiatory tradition. |
| Psilocybin-Assisted Early Palliative Care for Demoralization and Chronic Pain: An Open-Label Pilot Study. 2026 | open-label pilot study | 11 | Supports | Psilocybin-assisted therapy with multidisciplinary palliative care was safe, feasible, and acceptable, with 90% of dosed participants no longer meeting criteria for clinically significant demoralization and having pain scores below the enrollment threshold by study endpoint. |
| Reporting practices in psilocybin-assisted therapy trials for depression: A descriptive review and temporal overview 2026 | systematic review | Unclear | Reporting practices in psilocybin-assisted therapy trials are inconsistent, with poor reporting of blinding success, therapist fidelity, and expectancy, and an overrepresentation of participants with previous psychedelic experiences. | |
| Sex Differences in Acute Responses to Psychedelics: Evidence for Greater Subjective Intensity and Impairment in Female Participants 2026 | pooled analysis of two double-blind, placebo-controlled studies | 72 | Supports | Female participants experienced more intense acute subjective effects and greater perceived impairment under psychedelics than male participants, independent of age and not explained by drug exposure. |
| Acceptability and safety of two sequential doses of psilocybin in bipolar II depression: protocol for an open-label single-arm feasibility study. 2026 | phase II, single-arm, open-label clinical trial feasibility study | 10 | Unclear | The protocol aims to explore the acceptability, safety, and treatment preferences of psilocybin-assisted therapy in patients with bipolar II disorder struggling with suicidal ideation. |
| Psilocybin-induced behavioral and cellular effects. 2026 | experimental study | Supports | Psilocybin-induced c-Fos expression in the nucleus accumbens is mediated by 5-HT2A receptors in neurons and by 5-HT2B receptors in both neurons and non-neuronal cells. | |
| MDMA and Psilocybin-Assisted Therapy in Australia: Early Real-World Prescribing, Safety Monitoring and Regulatory Developments 2026 | review | Supports | Australia's regulatory pathway for MDMA and psilocybin prescriptions has grown rapidly but remains at an early stage, with authorized prescribers representing about 1% of the psychiatric workforce. | |
| Psychedelic-Assisted Psychosexual Therapy 2026 | review | Unclear | Proposes that classic serotonergic psychedelics, empathogenic-entactogenic agents, and glutamatergic dissociatives can enable direct engagement with traumatic, shame-laden, and affective antecedents of sexual difficulties by transiently altering states of consciousness and softening defensive avoidance. | |
| Therapeutic potential of psilocybin in the pharmacological treatment of obsessive-compulsive disorder: a scoping review protocol. 2026 | scoping review | Unclear | Psilocybin shows potential as an alternative pharmacological strategy for OCD, especially for treatment-resistant patients, but systematic evidence mapping is needed. | |
| Sex-specific outcomes of developmental stress and psilocybin intervention on the brain and behavior 2026 | preclinical animal study | Supports | Developmental stress produces distinct and often opposing behavioral and physiological effects in adult male and female mice, and psilocybin broadly reverses these effects through different behavioral domains in each sex. | |
| Psilocybin selectively rescues cognitive flexibility impairments caused by aberrant prefrontal error signaling 2026 | experimental study | Supports | Psilocybin rescues cognitive flexibility deficits caused by aberrant mesocortical signaling but not those from disrupted interhemispheric gamma synchrony, by attenuating pathological activity in prefrontal-mediodorsal thalamus neurons and inducing lasting plasticity. | |
| Psilocybin therapy for adult females with anorexia nervosa: pilot study. 2026 | single-blind, within-individual pilot study | 21 | Supports | Psilocybin therapy was associated with significant improvements in eating disorder symptoms and motivation to change in adult females with anorexia nervosa, with large individual variation in outcomes. |
| Entourage-Psilocybin-Ganzpilz 2026 | theoretical or philosophical paper | Unclear | Proposes that whole mushroom preparations may produce distinct effects compared to isolated psilocybin due to synergistic interactions among mushroom constituents, analogous to the entourage effect in cannabis. | |
| CSF galanin and noradrenaline downregulation by psilocybin therapy in major depressive disorder 2026 | secondary analysis of randomized, placebo-controlled trial | Supports | Psilocybin selectively reduced CSF galanin and noradrenaline, implicating normalization of these co-transmitters as a key pharmacodynamic signature. | |
| α2-Adrenergic receptor modulates 5-HT2A-mediated behavioral effects of MDMA and psilocybin in mice. 2026 | preclinical experimental study | Supports | Activation of the noradrenergic alpha-2 receptor suppresses serotonin 2A receptor-mediated head-twitch responses without blocking antidepressant-like effects in mice. |
Points of agreement
- Psilocybin shows therapeutic potential across multiple psychiatric conditions, including depression, demoralization, and anorexia nervosa, with consistent positive effects in clinical and preclinical studies.
- Mechanistic studies converge on the importance of 5-HT2A receptor signaling and brain state in mediating psilocybin's effects on neural plasticity and behavior.
- Context and setting appear to modulate psilocybin's effects, with therapeutic-like environments associated with greater benefits.
Conflicts
- One study found no significant overall increase in synaptic density after psilocybin, while another found context-dependent increases, suggesting that effects may be setting-specific.
- Sex differences in acute responses were reported, with females experiencing more intense effects, but another study found sex-dependent long-term effects in mice, indicating potential variability across species and outcomes.
Gaps
- Durability of effects beyond short-term follow-up is largely unstudied, with most trials reporting outcomes up to 6 months or less.
- Blinding success, therapist fidelity, and expectancy are poorly reported in psilocybin trials, limiting interpretation of efficacy.
- Most clinical studies have small sample sizes (e.g., 10-25 participants) and are open-label or pilot designs, lacking adequate control groups.
- Dose standardization is problematic due to batch-to-batch variability in natural products, complicating dose-response comparisons.
- Long-term safety and effects in underrepresented populations (e.g., bipolar disorder, OCD, anorexia) remain understudied.